These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36059951)

  • 21. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
    Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis.
    Gatti M; Fornaro G; Pasquini Z; Zanoni A; Bartoletti M; Viale P; Pea F
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of Insufficient Beta-Lactam Concentrations in Extracorporeal Membranous Oxygenation Patients.
    Polain A; Gorham J; Romeo I; Belliato M; Peluso L; Partipilo F; Njimi H; Brasseur A; Jacobs F; Creteur J; Hites M; Taccone FS
    Microorganisms; 2021 Oct; 9(11):. PubMed ID: 34835344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review.
    Mertens B; Elkayal O; Dreesen E; Wauters J; Meersseman P; Debaveye Y; Degezelle K; Vermeersch P; Gijsen M; Spriet I
    Antibiotics (Basel); 2023 Jun; 12(7):. PubMed ID: 37508181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole.
    Jia SJ; Gao KQ; Huang PH; Guo R; Zuo XC; Xia Q; Hu SY; Yu Z; Xie YL
    Front Pharmacol; 2021; 12():666296. PubMed ID: 34113252
    [No Abstract]   [Full Text] [Related]  

  • 26. Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Levkovich BJ; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Roberts JA; Shekar K; Fraser JF;
    Anaesth Crit Care Pain Med; 2022 Jun; 41(3):101080. PubMed ID: 35472580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variable Sequestration of Antifungals in an Extracorporeal Membrane Oxygenation Circuit.
    Lyster H; Pitt T; Maunz O; Diamond S; Roberts JA; Brown D; Mills J; Armstrong-James D; Gerovasili V; Carby M; Dunning J; Simon A; Reed A
    ASAIO J; 2023 Mar; 69(3):309-314. PubMed ID: 36731055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19.
    Bertram R; Naumann HT; Bartsch V; Hitzl W; Kinzig M; Haarmeyer GS; Baumgärtel M; Geise A; Muschner D; Nentwich J; John S; Sörgel F; Steinmann J; Höhl R
    Mycoses; 2023 Dec; 66(12):1071-1078. PubMed ID: 37700457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic value of oxygen challenge test for patients with cardiogenic shock receiving extracorporeal membrane oxygenation].
    Dong L; Zhang X; Liang F; Yu X; Yang T; Li L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Dec; 29(12):1102-1106. PubMed ID: 29216944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.
    Miller M; Kludjian G; Mohrien K; Morita K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1245-1249. PubMed ID: 35377411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study.
    Taher KW; Almofada R; Alomair S; Albassam AA; Alsultan A
    Paediatr Drugs; 2024 Mar; 26(2):197-203. PubMed ID: 38228969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of mortality in patients successfully weaned from extracorporeal membrane oxygenation.
    Chang WW; Tsai FC; Tsai TY; Chang CH; Jenq CC; Chang MY; Tian YC; Hung CC; Fang JT; Yang CW; Chen YC
    PLoS One; 2012; 7(8):e42687. PubMed ID: 22870340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation.
    Touchard C; Aubry A; Eloy P; Bréchot N; Lebreton G; Franchineau G; Besset S; Hékimian G; Nieszkowska A; Leprince P; Luyt CE; Combes A; Schmidt M
    Crit Care; 2018 Aug; 22(1):199. PubMed ID: 30121083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation.
    Van Daele R; Brüggemann RJ; Dreesen E; Depuydt P; Rijnders B; Cotton F; Fage D; Gijsen M; Van Zwam K; Debaveye Y; Wauters J; Spriet I
    J Antimicrob Chemother; 2021 Apr; 76(5):1234-1241. PubMed ID: 33517360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation.
    Surovoy YA; Burkin MA; Galvidis IA; Bochkov PO; Oganesyan AV; Tsarenko SV
    J Antimicrob Chemother; 2022 Apr; 77(5):1379-1384. PubMed ID: 35134959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit.
    Jaruratanasirikul S; Boonpeng A; Nawakitrangsan M; Samaeng M
    Pharmacotherapy; 2021 Jul; 41(7):572-597. PubMed ID: 34080708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).
    Kois AK; Gluck JA; Nicolau DP; Kuti JL
    Int J Antimicrob Agents; 2022 Jul; 60(1):106603. PubMed ID: 35577257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study.
    Donadello K; Roberts JA; Cristallini S; Beumier M; Shekar K; Jacobs F; Belhaj A; Vincent JL; de Backer D; Taccone FS
    Crit Care; 2014 Nov; 18(6):632. PubMed ID: 25416535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
    Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
    Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.